Overview

• Under the July 10 agreement, eight manufacturers will pay $720 million to states over terms ranging from one to ten years.
• All companies except Indivior face bans on marketing opioids and must cap oxycodone pills at 40 mg with enhanced order monitoring.
• Indivior will stop all opioid product sales for ten years but may continue making medications for opioid use disorder.
• Pennsylvania is set to receive up to $28 million based on county participation, while Minnesota could collect about $9.4 million, boosting its opioid funds to $633 million since 2022.
• States will deploy these payments to expand prevention, treatment and recovery programs under various local distribution frameworks.